

**IN THE CLAIMS:**

**Listing of Claims:**

1-30 (Cancelled).

31. (Currently amended) A method for treatment of a metabolic disorder or condition related to an  $\alpha$ -galactosidase A deficiency, said method comprising administering to a subject in need thereof an effective, non-toxic amount of a pharmaceutical composition and a pharmaceutically acceptable carrier, said pharmaceutical composition comprising comprises:

- (a) an expression cassette operably linked to:
  - (i) a myosin light chain enhancer;
  - (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and
  - (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use; or
- (b) a vector comprising said expression cassette; or
- (c) a viral strain comprising said expression cassette combined with a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) The method of claim 31, wherein said vector is a plasmid vector or a viral vector.

33. (Previously presented) The method of claim 31, wherein said expression cassette is administered as a naked nucleic acid construct.

34. (Previously presented) The method of claim 31, wherein said pharmaceutical composition is formulated for intramuscular administration.

35. (Previously presented) The method of claim 31, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

36-39 (Cancelled).

40. (Previously presented) The method of claim 31, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

41. (Currently amended) The method of claim 31, wherein said vector comprises fish or mammalian the expression cassette flanked by a genomic sequences flanking said expression cassette, wherein said genomic sequence is homologous to an eukaryotic genomic sequence.

42. (Currently amended) The method of claim 31, wherein said vector comprises viral the expression cassette flanked by a genomic sequences flanking said expression cassette, wherein said genomic sequence is homologous to a viral genomic sequence.

43-50 (Cancelled).

51. (Previously presented) The method of claim 31, wherein said polynucleotide

sequence comprises a heterologous gene.

52-57 (Cancelled).

58. (Currently amended) A method for treatment of a metabolic disorder or condition related to an  $\alpha$ -galactosidase A deficiency, said method comprising administering to a subject in need thereof an effective, non-toxic amount of a pharmaceutical composition and a pharmaceutically acceptable carrier, said pharmaceutical composition comprising comprises:

- (a) an expression cassette operably linked to:
  - (i) a myosin light chain enhancer;
  - (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and
  - (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use which is not a blood coagulation factor; or
- (b) a vector comprising said expression cassette; or
- (c) a viral strain comprising said expression cassette combined with a pharmaceutically acceptable carrier or diluent.

59. (Previously presented) The method of claim 58, wherein said vector is a plasmid vector or a viral vector.

60. (Previously presented) The method of claim 58, wherein said expression cassette is administered as a naked nucleic acid construct.

61. (Previously presented) The method of claim 58, wherein said pharmaceutical composition is formulated for intramuscular administration.

62. (Previously presented) The method of claim 58, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

63-66 (Cancelled).

67. (Previously presented) The method of claim 58, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

68. (Currently amended) The method of claim 58, wherein said vector comprises fish or mammalian the expression cassette flanked by a genomic sequences flanking said expression cassette, wherein said genomic sequence is homologous to an eukaryotic genomic sequence.

69. (Currently amended) The method of claim 31, wherein said vector comprises viral the expression cassette flanked by a genomic sequences flanking said expression cassette, wherein said genomic sequence is homologous to a viral genomic sequence.

70-77 (Cancelled)

78. (Previously presented) The method of claim 58, wherein said polynucleotide sequence comprises a heterologous gene.

79-96. (Cancelled).

97. (Previously presented) The method of claim 31 or 58, wherein the subject in need of treatment is an animal.

98. (Previously presented) The method of claim 97, wherein the animal is a human.

99. (New) The method of claim 41 or 68, wherein said eukaryotic genomic sequence is a fish or mammalian genomic sequence.